Ardelyx Data Shows IBSRELA Cuts Healthcare Visits for IBS-C Patients

  • Ardelyx presented real-world data at ACG 2026 showing a significant reduction in GI-related healthcare visits for IBS-C patients after starting IBSRELA.
  • Median GI-related healthcare resource utilization dropped from 4.5 visits to 3.0 visits in the year following IBSRELA initiation.
  • Ardelyx also presented data on IBS-C symptom burden and the design of a Phase 3 study for chronic idiopathic constipation (CIC).
  • The analysis included 470 patients with IBS-C from a national gastroenterology practice.

Ardelyx's data underscores the potential of IBSRELA to reduce healthcare resource utilization for IBS-C patients, a strategic advantage in a market where symptom management and quality of life are critical. The company's focus on real-world evidence aligns with broader industry trends toward value-based healthcare, where demonstrating tangible patient outcomes can drive market differentiation and reimbursement strategies. The ongoing Phase 3 study for CIC represents a significant opportunity to expand the drug's addressable market.

Clinical Validation
Whether the real-world data will translate into broader adoption of IBSRELA for IBS-C and potential expansion into CIC.
Market Differentiation
How Ardelyx positions IBSRELA against existing treatments in the IBS-C and CIC markets.
Regulatory Pathway
The pace at which Ardelyx advances its Phase 3 study for CIC and secures regulatory approvals.